PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
25-Sep-2024 Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers Lantern Pharma
25-Sep-2024 Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference AccessWire
25-Sep-2024 Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion
25-Sep-2024 New data show Almirall´s EBGLYSS® (lebrikizumab) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis Almirall
25-Sep-2024 Semaglutide improves outcomes for obese patients with common skin condition, new study shows European Academy of Dermatology and Venereology (EADV)
25-Sep-2024 Arctoris announces strategic partnership with Alphabet company, Isomorphic Labs Arctoris
25-Sep-2024 Royal Columbian Hospital Foundation’s Advancing Innovation in Medicine (AIM) division supports Steriwave ICU use with clinical trials at Royal Columbian Hospital Ondine Biomedical Inc
25-Sep-2024 Univo IRB Launches Canadian Research Ethics Board Review Services for Clinical Trials in North America Univo IRB
25-Sep-2024 Coave Therapeutics to Present Novel Data Highlighting the Potential of its ALIGATER™ Platform to Enhance the Targeted Delivery of Genetic Medicines at Upcoming Conferences Coave Therapeutics
25-Sep-2024 Combination treatment improves response to immunotherapy for lung cancer Francis Crick Institute
25-Sep-2024 Quell Therapeutics expands manufacturing capabilities for CAR-Treg cell therapy pipeline through partnership with eXmoor pharma Quell Therapeutics
25-Sep-2024 Panthera moves back into recruiting and running commercial oncology clinical trials in the UK Panthera Biopartners
25-Sep-2024 Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia CSL Vifor
25-Sep-2024 Oxford-Harrington Rare Disease Centre to Host Symposium on Pioneering Research and Innovation in Rare Disease Treatments The Oxford-Harrington Rare Disease Centre
25-Sep-2024 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda HUTCHMED
25-Sep-2024 AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy AlgoTherapeutix
25-Sep-2024 Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia Nxera Pharma
25-Sep-2024 Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy Santhera Pharmaceuticals
25-Sep-2024 Quasar Medical Acquires Ridgeback Technologies AccessWire
25-Sep-2024 SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders AccessWire